gilaxia / iStockphoto.com
BACIT, a former fund of funds, has combined with life sciences investment company Syncona to form a new investment vehicle using the latter’s name. LSIPR speaks to Arabella Cecil, one of the co-founders of BACIT, about the new company’s vision.
In 2012, there was a gap in the life sciences investment market.
Charities and researchers were faced with living hand to mouth—they received lump sums but were not sure whether they could spend the money and, if so, at what rate, because they didn’t know when the next payment was coming in.
That’s according to Arabella Cecil, a co-founder of what was, until December last year, investment fund BACIT, which is now known as Syncona after a combination of the businesses.
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
European Patent Office
George Washington Law School
Kirkland & Ellis International LLP
Marks & Clerk
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
The United States Patent and Trademark Office (USPTO)
World Intellectual Property Office
Arabella Cecil, Syncona, LSIPR 50 2017, researchers, BACIT, Syncona, life sciences, researchers,